REGN Regeneron Pharmaceuticals Inc.

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • Oppenheimer 34th Annual Healthcare Life Sciences Conference at 1:20 p.m. ET on Wednesday, February 14, 2024



  • TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Wednesday, March 6, 2024



  • Barclays 26th Annual Global Healthcare Conference at 11:15 a.m. ET on Tuesday, March 12, 2024



  • Leerink Partners Global Biopharma Conference 2024 at 10:40 a.m. ET on Wednesday, March 13, 2024

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit  or follow Regeneron on .

Contact Information:

Investor Relations

Ryan Crowe

914.847.8790

        



EN
06/02/2024

Underlying

REGNRegeneron Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE
Free
REGN Regeneron Pharm...

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforc...

Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone In a five-year analysis, consistent efficacy was observed across histologies with especially notable benefit in the squamous patient population where median overall survival was 22.3 months TARRYTOWN, N.Y., Sept. 09, 2025 (G...

12h / 5m 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials E...

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support further Phase 3 development TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in allergen-challenge Phas...

September 8, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Announces Updated Presentation Time for Upcoming Investor Co...

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 7:00 a.m. ET on Monday, September 8, 2025. The presentation will be webcast live and may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ: REGN) ...

September 4, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Announces Positive Results from Phase 3 Trial in Generalized...

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondar...

August 26, 2025 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. ...

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA HD prefilled syringe and a supplemental Biologics Lic...

August 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch